Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 14 studies | 27% ± 7% | |
lung | 8 studies | 24% ± 10% | |
brain | 6 studies | 27% ± 10% | |
intestine | 6 studies | 21% ± 8% | |
eye | 5 studies | 29% ± 9% | |
pancreas | 3 studies | 21% ± 8% | |
kidney | 3 studies | 17% ± 1% | |
bone marrow | 3 studies | 19% ± 2% | |
liver | 3 studies | 26% ± 11% | |
lymph node | 3 studies | 20% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1558.15 | 1445 / 1445 | 100% | 45.55 | 183 / 183 |
ovary | 100% | 2442.17 | 180 / 180 | 100% | 60.99 | 430 / 430 |
prostate | 100% | 1615.54 | 245 / 245 | 100% | 72.58 | 502 / 502 |
stomach | 100% | 1329.91 | 359 / 359 | 100% | 49.23 | 286 / 286 |
uterus | 100% | 1998.92 | 170 / 170 | 100% | 60.67 | 459 / 459 |
breast | 100% | 2383.86 | 459 / 459 | 100% | 82.43 | 1117 / 1118 |
kidney | 100% | 1434.79 | 89 / 89 | 100% | 53.12 | 898 / 901 |
intestine | 100% | 2195.63 | 966 / 966 | 100% | 56.18 | 525 / 527 |
bladder | 100% | 1751.95 | 21 / 21 | 100% | 52.86 | 502 / 504 |
liver | 100% | 963.49 | 226 / 226 | 100% | 40.67 | 404 / 406 |
thymus | 100% | 1815.32 | 653 / 653 | 100% | 85.15 | 602 / 605 |
lung | 99% | 1418.28 | 575 / 578 | 100% | 61.21 | 1155 / 1155 |
brain | 99% | 1378.74 | 2626 / 2642 | 100% | 66.44 | 705 / 705 |
adrenal gland | 100% | 2097.88 | 258 / 258 | 99% | 55.33 | 228 / 230 |
skin | 100% | 2413.34 | 1809 / 1809 | 99% | 49.26 | 465 / 472 |
pancreas | 98% | 858.07 | 321 / 328 | 100% | 51.18 | 178 / 178 |
adipose | 100% | 2033.72 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1986.25 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 58.87 | 29 / 29 |
spleen | 100% | 1778.06 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 57.37 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 23.45 | 1 / 1 |
muscle | 100% | 1300.49 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 824.54 | 833 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 45.59 | 77 / 80 |
peripheral blood | 96% | 1353.19 | 892 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0034244 | Biological process | negative regulation of transcription elongation by RNA polymerase II |
GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | EAPP |
Protein name | E2F associated phosphoprotein E2F-associated phosphoprotein (EAPP) Alternative protein EAPP |
Synonyms | C14orf11 BM-036 |
Description | FUNCTION: May play an important role in the fine-tuning of both major E2F1 activities, the regulation of the cell-cycle and the induction of apoptosis. Promotes S-phase entry, and inhibits p14(ARP) expression. . |
Accessions | ENST00000555705.1 G3V5N6 L8EAZ8 G3V2W9 ENST00000554792.1 Q56P03 ENST00000250454.8 |